化合物TAS1553 T60217

Product Introduction
Bioactivity


英文名: TAS1553

描述: TAS1553是一种高效的可口服蛋白质-蛋白质相互作用(PPI)抑制剂，其IC50值为0.0396 μM。TAS1553 有效地阻碍DNA复制并减少细胞内dATP池。此外，TAS1553诱导凋亡，[1]使其在癌症研究中极具价值。

体外活性: TAS1553 (0.001-1 μM) dose-dependently inhibits the enzymatic activity of RNR [1]. TAS1553 (3 d) has anti-proliferative activity against both solid and hematological human cancer cell lines and the GI 50 values ranged from 0.228 to 4.15 μM [1]. TAS1553 (1-10 μM; 0-2 h; HCC38 and MV-4-11 cells) reduces intracellular dATP pool in a dose- and time-dependent manner, which is a critical metabolite for DNA replication [1]. TAS1553 (0-10 μM; 0-24 h; HCC38 and MV-4-11 cells) induces the replication stress and apoptosis in a dose- and time-dependent manner [1]. Western Blot Analysis [1] Cell Line: HCC38 and MV-4-11 cells Concentration: 0, 0.1, 0.3, 1, 3 and 10 μM Incubation Time: 0, 1, 2, 4, 8 and 24 hours Result: Increased the expression of Ser345, Ser4, Ser8 and Thr21 phosphorylation. Increaed the levels cleaved PARP and cleaved caspase-3.

体内活性: TAS1553 (25-200 mg/kg; p.o.; for 24 h; female F344/NJcl-rnu/rnu rats and BALB/cAJcl-nu/nu mice) shows RNR inhibitory effect in vivo [1]. TAS1553 (50-200 mg/kg; p.o.; daily, for 15 d; female F344/NJcl-rnu/rnu rats and BALB/cAJcl-nu/nu mice) has antitumor activity in vivo [1]. Animal Model: Female F344/NJcl-rnu/rnu rats and BALB/cAJcl-nu/nu mice [1] Dosage: 25, 50, 100 and 200 mg/kg Administration: Oral administration; for 24hours Result: Reduces intracellular dATP pool and induces the replication stress and apoptosis. Animal Model: Female F344/NJcl-rnu/rnu rats and BALB/cAJcl-nu/nu mice [1] Dosage: 50, 100 and 200 mg/kg Administration: Oral administration; daily, for 15 days Result: Inhibited tumor growth in the treated group/control group (T/C) were 52.0 (50 mg/kg), 45.0 (100 mg/kg) and 29.4% (200 mg/kg), respectively.

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 90 mg/mL (186.4 mM)


关键字: TAS 1553 | TAS-1553 | TAS1553

相关库: Drug Repurposing Compound Library | Anti-Cancer Compound Library | Anti-Cancer Drug Library | Clinical Compound Library | Bioactive Compounds Library Max | Anti-Cancer Clinical Compound Library | Inhibitor Library | Anti-Cancer Active Compound Library | PPI Inhibitor Library | Bioactive Compound Library

化合物TAS1553 T60217信息由TargetMol中国为您提供，如您想了解更多关于化合物TAS1553 T60217报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途